Session Type
Date Time

This session reviews ongoing and planned clinical development activities for the various major research initiatives advancing passive administration of bNAbs for prevention. Speakers will review their respective program strategies, target product profiles, timelines for candidates in development and ongoing research into next-generation optimized bNAb candidates. This session also looks at the potential role of bNAbs as part of the broader HIV prevention landscape, including vaccines and long-acting ARVs, and the evolving complexities of clinical efficacy trial design.

RT01.01 Optimization of bNAbs for HIV prevention
Devin SOK, International AIDS Vaccine Initiative Neutralizing Antibody Center, United States
RT01.02 Engineered bispecific bNAbs
Magdalena SOBIESZCZYK, Columbia University Medical Centre, United States

RT01.03 Preclinical to clinical: 3BNC117 and 10-1074 bNAb combination for HIV prophylaxis
Marina CASKEY, The Rockefeller University, United States

RT01.04 Passive bNAb infusion pipeline
Lynn MORRIS, National Institute for Communicable Diseases, South Africa

RT01.05 Antibodies against COVID-19
Marit VAN GILS, Academic Medical Center, Netherlands
RT01.06 Panel discussion